Bloodwork Before Starting BPC-157

Why Baseline Bloodwork Matters for BPC-157

BPC-157 is a gastric pentadecapeptide that drives tissue repair through two converging angiogenic pathways, both terminating in nitric oxide production via eNOS activation. It upregulates VEGFR2 signaling, promotes new blood vessel formation, and modulates inflammatory cascades through heme oxygenase-1 and heat shock protein expression. These mechanisms mean that BPC-157 actively reshapes inflammatory tone and vascular biology from the first dose. Without a pre-protocol snapshot of your inflammatory markers and liver function, you have no way to distinguish a therapeutic response from an adverse one. Baseline bloodwork gives your provider an objective reference point — a before picture that makes every follow-up panel interpretable rather than ambiguous. It also screens for pre-existing hepatic stress or elevated inflammation that could complicate therapy or mask underlying pathology.

What to Test Before Starting

Two categories of labs matter before your first dose of BPC-157: inflammatory markers and hepatic function panels.

On the inflammatory side, draw CRP as your primary baseline. C-reactive protein is the most accessible systemic inflammation marker, and because BPC-157 is expected to normalize and eventually decrease CRP through its anti-inflammatory cascade, you need a clean starting value. If your CRP is already elevated at baseline, that tells your provider something important about your current inflammatory load and may change the monitoring cadence.

For hepatic function, draw ALT/AST before starting therapy. BPC-157 research demonstrates hepatoprotective effects and normalization of liver enzymes in preclinical models, but that normalization only means something if you know where you started. Elevated transaminases at baseline could indicate pre-existing liver stress that needs its own workup before layering on a peptide protocol. Normal baseline values, on the other hand, give you a clean reference to confirm that BPC-157 is not introducing hepatic strain over the course of therapy.

Request these labs through your prescribing provider or an independent lab service. Fasting is not strictly required for CRP or liver enzymes, but drawing them fasted and in the morning provides the most consistent and comparable values across follow-up panels.

What to Retest and When

At eight weeks into your BPC-157 protocol, retest CRP and ESR together. Both are inflammatory markers that BPC-157 is expected to decrease during active therapy, and drawing them simultaneously gives your provider a more complete picture of systemic inflammation than either marker alone. At the same eight-week mark, retest your liver enzyme panel. BPC-157 should normalize liver enzymes during use, and this draw confirms that pattern is holding or flags early deviation.

If your provider also wants to track TNF-alpha, the eight-week point is the appropriate window for that draw as well. TNF-alpha is a more specific inflammatory cytokine that BPC-157 is expected to decrease, though it requires a specialty lab order at most facilities.

After completing your protocol, repeat the full panel one more time to confirm that inflammatory markers have settled and liver function remains stable. Discuss the post-protocol timeline with your prescribing provider, as individual factors like concurrent medications and pre-existing conditions influence how quickly biomarkers stabilize.

Red Flags — When to Pause and Retest

If you have a history of active cancer, the angiogenic activity of BPC-157 is a theoretical concern that warrants serious discussion with your oncologist before starting or continuing therapy. If you are taking anticoagulants, monitor for unusual bruising or changes in clotting behavior, as BPC-157 may interact with the wound healing cascade. If mid-protocol labs show rising liver enzymes or worsening inflammatory markers rather than the expected improvement, pause the protocol and consult your provider before resuming.

How This Fits Your Broader Protocol

BPC-157 is frequently combined with other peptides in structured protocols. If you are stacking compounds, each one may carry its own biomarker monitoring requirements. Review the full BPC-157 contraindications page before finalizing your stack, and use the interaction checker to screen for conflicts between BPC-157 and any concurrent medications or peptides.